Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Olaparib> ?p ?o. }
Showing items 1 to 67 of
67
with 100 items per page.
- Olaparib abstract "Olaparib (AZD-2281) is an experimental chemotherapeutic agent, developed by KuDOS Pharmaceuticals and later by AstraZeneca, that is currently undergoing clinical trials. It is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which includes many ovarian, breast and prostate cancers. Early Phase I trials were promising, and olaparib underwent Phase II trials. However, in December 2011, AstraZeneca announced following interim analysis of a phase-II study which indicated that the previously reported progression free survival benefit was unlikely to translate into an overall survival benefit, that it would not progress into Phase III development for the maintenance treatment of serous ovarian cancer, and took a charge of $285 million. The decision to discontinue development of the drug was reversed in 2013, with Astrazeneca posting a new Phase III trial of Olaparib for patients with BRCA mutated ovarian cancer in April 2013.".
- Olaparib atcPrefix "none".
- Olaparib casNumber "763113-22-0".
- Olaparib fdaUniiCode "WOH1JD9AR8".
- Olaparib iupacName "4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl) -4-fluorophenyl]methyl(2H)phthalazin-1-one".
- Olaparib pubchem "23725625".
- Olaparib thumbnail Olaparib.png?width=300.
- Olaparib wikiPageID "23381962".
- Olaparib wikiPageRevisionID "600574016".
- Olaparib atcPrefix "none".
- Olaparib c "24".
- Olaparib casNumber "763113".
- Olaparib chembl "521686".
- Olaparib chemspiderid "23343272".
- Olaparib f "1".
- Olaparib h "23".
- Olaparib hasPhotoCollection Olaparib.
- Olaparib inchi "1".
- Olaparib inchikey "FDLYAMZZIXQODN-UHFFFAOYAF".
- Olaparib iupacName "4".
- Olaparib legalStatus "Investigational".
- Olaparib molecularWeight "435.08".
- Olaparib n "4".
- Olaparib o "3".
- Olaparib pubchem "23725625".
- Olaparib routesOfAdministration "Oral".
- Olaparib smiles "c4cccc2c4cCccc1CN3CCNCC5CC5".
- Olaparib stdinchi "1".
- Olaparib stdinchikey "FDLYAMZZIXQODN-UHFFFAOYSA-N".
- Olaparib unii "WOH1JD9AR8".
- Olaparib verifiedfields "changed".
- Olaparib verifiedrevid "462264805".
- Olaparib width "200".
- Olaparib subject Category:Amides.
- Olaparib subject Category:Experimental_cancer_drugs.
- Olaparib subject Category:Lactams.
- Olaparib subject Category:Organofluorides.
- Olaparib subject Category:PARP_inhibitors.
- Olaparib subject Category:Phthalazines.
- Olaparib subject Category:Piperazines.
- Olaparib type Agent114778436.
- Olaparib type Antineoplastic102722458.
- Olaparib type CausalAgent100007347.
- Olaparib type CytotoxicDrug103157987.
- Olaparib type Drug103247620.
- Olaparib type ExperimentalCancerDrugs.
- Olaparib type Inhibitor114724436.
- Olaparib type Matter100020827.
- Olaparib type Medicine103740161.
- Olaparib type PARPInhibitors.
- Olaparib type PhysicalEntity100001930.
- Olaparib type Piperazine103946814.
- Olaparib type Piperazines.
- Olaparib type Substance100020090.
- Olaparib type Vermifuge104528630.
- Olaparib type Drug.
- Olaparib type DrugProduct.
- Olaparib type FunctionalSubstance.
- Olaparib comment "Olaparib (AZD-2281) is an experimental chemotherapeutic agent, developed by KuDOS Pharmaceuticals and later by AstraZeneca, that is currently undergoing clinical trials. It is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which includes many ovarian, breast and prostate cancers. Early Phase I trials were promising, and olaparib underwent Phase II trials.".
- Olaparib label "Olaparib".
- Olaparib sameAs m.06wb9bt.
- Olaparib sameAs Q7083106.
- Olaparib sameAs Q7083106.
- Olaparib sameAs Olaparib.
- Olaparib wasDerivedFrom Olaparib?oldid=600574016.
- Olaparib depiction Olaparib.png.
- Olaparib isPrimaryTopicOf Olaparib.
